Ginkgo Bioworks Holdings Revenue 2020-2022 | DNA

Ginkgo Bioworks Holdings revenue from 2020 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Ginkgo Bioworks Holdings Annual Revenue
(Millions of US $)
2021 $314
2020 $77
2019 $54
Ginkgo Bioworks Holdings Quarterly Revenue
(Millions of US $)
2022-03-31 $168
2021-12-31 $192
2021-09-30 $78
2021-06-30
2021-03-31 $44
2020-12-31
2020-09-30 $13
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.637B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $167.557B 10.19
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.634B 16.78
Biohaven Pharmaceutical Holding (BHVN) United States $10.186B 0.00
Arcus Biosciences (RCUS) United States $1.751B 44.40
Emergent Biosolutions (EBS) United States $1.570B 6.72
Myovant Sciences (MYOV) United Kingdom $1.212B 0.00
Zymeworks (ZYME) Canada $0.325B 0.00
Gelesis Holdings (GLS) United States $0.111B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.091B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00